Study Name:
RESOLUTE: Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Targeted Disease(s):
COPD
Purpose of Study:
We are looking for people with chronic obstructive pulmonary disease (COPD) who need to improve their disease control further. RESOLUTE is a study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils. Eosinophils are a type of blood cell that helps the body to fight infections and is involved in inflammation, immune and allergic reactions. Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count.
Study Dates:
August 26, 2019 - June 27, 2025
Study Location:
Nationwide
Lead Institution:
Temple University School of Medicine
Sponsors:
AstraZeneca
Contact:
Phone: 1-877-240-9479
Email: information.center@astrazeneca.com
ClinicalTrails.gov Identifier:
NCT04053634
